Charles Michaud Jr. - 17 Nov 2023 Form 3 Insider Report for Homology Medicines, Inc. (QTTB)

Role
Exhibit 24 - Power of Attorney. Vice President, Corporate Controller and Treasurer
Signature
/s/ Paul Alloway, Attorney-in-Fact for Charles Michaund, Jr.
Issuer symbol
QTTB
Transactions as of
17 Nov 2023
Net transactions value
$0
Form type
3
Filing time
17 Nov 2023, 16:05:19 UTC
Previous filing
11 Dec 2023
Next filing
03 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding FIXX Common Stock 2,112 17 Nov 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding FIXX Employee Stock Option (Right to Buy) 17 Nov 2023 Common Stock 25,000 $15.58 Direct F1
holding FIXX Employee Stock Option (Right to Buy) 17 Nov 2023 Common Stock 9,800 $13.91 Direct F2
holding FIXX Employee Stock Option (Right to Buy) 17 Nov 2023 Common Stock 19,300 $2.71 Direct F3
holding FIXX Employee Stock Option (Right to Buy) 17 Nov 2023 Common Stock 49,000 $1.60 Direct F4
holding FIXX Restricted Stock Units 17 Nov 2023 Common Stock 544 Direct F5, F6
holding FIXX Restricted Stock Units 17 Nov 2023 Common Stock 2,144 Direct F6, F7
holding FIXX Restricted Stock Units 17 Nov 2023 Common Stock 8,000 Direct F6, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests or has vested as to 25% of the underlying shares on June 8, 2021 and in 36 substantially equal monthly installments upon the Reporting Person's completion of each full month of service thereafter so that such option will become fully vested on June 8, 2024.
F2 The option vests in 48 substantially equal monthly installments upon the Reporting Person's completion of each full month of service following January 1, 2021 such that the option will become fully vested on January 1, 2025.
F3 The option vests in 48 substantially equal monthly installments upon the Reporting Person's completion of each full month of service following January 1, 2022 so that such option will become fully vested on January 1, 2026.
F4 The option vests in 48 substantially equal monthly installments upon the Reporting Person's completion of each full month of service following January 1, 2023 so that such option will become fully vested on January 1, 2027.
F5 The restricted stock units will vest and settle in full on January 1, 2024.
F6 Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units have no expiration date.
F7 The restricted stock units will vest and settle as to 1,056 shares on January 1, 2024 and 1,088 shares on January 1, 2025.
F8 The restricted stock units will vest and settle as to one-third of the restricted stock units on each of the first three anniversaries of January 1, 2023.

Remarks:

Exhibit 24 - Power of Attorney. Vice President, Corporate Controller and Treasurer